Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.63 |
| ▸ | DPYD | Q12882 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorouracil SCHEMBL29265212 | 0.88 | LMNA (0.56) | ATAD2DPYDALDH1A1MAPTGAA | |
| SCHEMBL17978585 | 0.88 | DPYD (0.56) | ATAD2DPYDALDH1A1MAPTGAA | |
| SCHEMBL1231792 | 0.86 | ATAD2 (0.37) | ATAD2CYP1A2 | |
| SCHEMBL30609151 | 0.86 | — | — | |
| SCHEMBL22008 | 0.86 | — | — | |
| SCHEMBL17373188 | 0.85 | ATAD2 (0.45) | ATAD2DPYDALDH1A1GAALMNA | |
| SCHEMBL31403153 | 0.84 | ATAD2 (0.35) | ATAD2CYP1A2 | |
| SCHEMBL30917957 | 0.84 | ATAD2 (0.35) | ATAD2CYP1A2 | |
| Water SCHEMBL28196064 | 0.84 | ATAD2 (0.35) | ATAD2CYP1A2KDM4E | |
| Hydrochloric Acid SCHEMBL2199283 | 0.84 | ATAD2 (0.35) | ATAD2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | MODERNATX, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20210071239-A1 | METHODS FOR DETERMINING BASE LOCATIONS IN A POLYNUCLEOTIDE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-03-11 | — | — | US | disclosed |
| EP-3768834-A1 | NOVEL RNA-PROGRAMMABLE ENDONUCLEASE SYSTEMS AND USES THEREOF | CRISPR Therapeutics AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| EP-3724332-A1 | NOVEL RNA-PROGRAMMABLE ENDONUCLEASE SYSTEMS AND THEIR USE IN GENOME EDITING AND OTHER APPLICATIONS | CRISPR Therapeutics AG (CH) | 2020-10-21 | — | — | EP | disclosed |
| US-10760117-B2 | Methods for determining base locations in a polynucleotide | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190298658-A1 | Polynucleotides Encoding Cystic Fibrosis Transmembrane Conductance Regulator for the Treatment of Cystic Fibrosis | MODERNATX, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| WO-2019183150-A1 | NOVEL RNA-PROGRAMMABLE ENDONUCLEASE SYSTEMS AND USES THEREOF | CASEBIA THERAPEUTICS LIMITED LIABILITY PARTNERSHIP (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019118935-A1 | NOVEL RNA-PROGRAMMABLE ENDONUCLEASE SYSTEMS AND THEIR USE IN GENOME EDITING AND OTHER APPLICATIONS | CASEBIA THERAPEUTICS LIMITED LIABILITY PARTNERSHIP (US) | 2019-06-20 | — | — | WO | disclosed |
| EP-3458108-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ModernaTX, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | QIAGEN GMBH (DE) | 2005-12-29 | — | — | US | disclosed |
| EP-1557424-A1 | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues | Exiqon A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| EP-1015469-B1 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2005-04-13 | — | — | EP | disclosed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
| US-20030144231-A1 | Oligonucleotide analogues | EXIQON A/S (DK) | 2003-07-31 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
| US-20020068708-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2002-06-06 | — | — | US | disclosed |
| EP-1015469-A2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | Exiqon A/S (DK) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999014226-A2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068708-A1 | OLIGONUCLEOTIDE ANALOGUES | DCLRE1B, TARBP1, NCL | ATAD2 2257/4885DPYD 149/4885ALDH1A1 3261/4885 |
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | ATAD2 2152/4885DPYD 188/4885ALDH1A1 3403/4885 |
| US-20030144231-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | ATAD2 2152/4885DPYD 188/4885ALDH1A1 3403/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | ATAD2 3825/4885DPYD 3463/4885ALDH1A1 3662/4885 |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | CFTR, SLC47A1, TMEM205 | ATAD2 3825/4885DPYD 3463/4885ALDH1A1 3662/4885 |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | POLRMT, POLM, POLN | ATAD2 1678/4885DPYD 222/4885ALDH1A1 4268/4885 |
| US-20190298658-A1 | Polynucleotides Encoding Cystic Fibrosis Transmembrane Conductance Regulator for the Treatment of Cystic Fibrosis | CFTR, SLC47A1, TMEM205 | ATAD2 3825/4885DPYD 3463/4885ALDH1A1 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.